Pharmaceutical Following the recent news that Biogen’s Vumerity (diroximel fumarate) was granted marketing authorization by the European Commission for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS), GlobalData, a data and analytics company GlobalData expects Vumerity to claim market share in Europe both from new RRMS patients starting on an oral fumarate treatment, as well as those who cannot tolerate the gastrointestinal side effects of its predecessor, Tecfidera. 30 November 2021